| name | jes-pa-mra-selection |
| description | Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA therapy and asking 'Which MRA should I prescribe?' or considering switching agents due to adverse effects, cost, or need for potassium supplementation. |
Select appropriate mineralocorticoid receptor antagonist for PA treatment
STEP 1 — Gather Information
Collect gender, pregnancy status, need for potassium supplementation, history of gynecomastia, renal/hepatic function, cost/insurance coverage, and patient preference.
→ Proceed to assess potassium supplementation need.
STEP 2 — Rule In / Rule Out
If the patient requires potassium supplementation → select spironolactone (can be combined with K+ prep) and arrange K+ and creatinine monitoring; else → proceed to evaluate gynecomastia risk.
→ Proceed to assess gynecomastia concern.
STEP 3 — Classify or Stratify
If the patient is male with concern for gynecomastia → exclude spironolactone and consider eplerenone or esaxerenone; else → consider all three MRAs.
→ Proceed to final selection based on cost, adverse effect profile, and tolerability.
STEP 4 — Decide
Choose the MRA that best balances cost, adverse effect profile (e.g., esaxerenone lower gynecomastia risk but limited long-term data), and patient preferences; prescribe at starting dose (spironolactone 25 mg daily, eplerenone 2.5 mg daily, esaxerenone 1.25 mg daily) with potassium and renal monitoring.
→ Initiate selected MRA and schedule follow‑up in 1–2 weeks.
Clinical Guardrails / Mimics / Pitfalls
- Avoid eplerenone or esaxerenone with potassium supplements due to heightened hyperkalemia risk.
- Avoid spironolactone in pregnancy (anti‑androgen effects); consider eplerenone or esaxerenone if pregnancy is planned.
- Monitor serum potassium and creatinine within 1–2 weeks of initiation and periodically thereafter.
- Watch for spironolactone‑induced gynecomastia in males and menstrual irregularities in females.
- Consider cost and insurance coverage; esaxerenone may have less long‑term outcome data than spironolactone or eplerenone.
- In severe renal impairment, all MRAs require caution; follow dosing restrictions per label.
Concrete Clinical Example
A 62‑year‑old male with bilateral PA presents with persistent hypokalemia requiring oral potassium chloride. He has no gynecomastia concern. Because he needs potassium supplementation, spironolactone is selected (can be combined with K+ prep). Start spironolactone 25 mg daily; check potassium and creatinine in 1 week.
Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021, DOI: 10.1007/s00223-022-00903-5
